| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Xilio Therapeutics, Inc. | 10%+ Owner | Common Stock | 1,613,632 | $1,339,315 | $0.8300 | 26 Oct 2021 | Direct |
| Xilio Therapeutics, Inc. | 10%+ Owner | Common Stock | 1,613,632 | $1,339,315 | $0.8300 | 26 Oct 2021 | Indirect |
| Xilio Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | 26 Oct 2021 | Direct | ||
| Xilio Therapeutics, Inc. | 10%+ Owner | Series B Convertible Preferred Stock | 0 | 26 Oct 2021 | Indirect | ||
| Xilio Therapeutics, Inc. | 10%+ Owner | Series C Convertible Preferred Stock | 0 | 26 Oct 2021 | Direct | ||
| Xilio Therapeutics, Inc. | 10%+ Owner | Series C Convertible Preferred Stock | 0 | 26 Oct 2021 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| XLO | Xilio Therapeutics, Inc. | 26 Oct 2021 | 10 | +$10,000,000 | 4/A | 10%+ Owner | 03 Nov 2021, 16:20 |
| XLO | Xilio Therapeutics, Inc. | 21 Oct 2021 | 0 | $0 | 3 | 10%+ Owner | 21 Oct 2021, 20:40 |